Clinical Trial

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

Study acronym: ICONIC-CD
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate how-well icotrokinra works (clinical efficacy) and how safe it is (safety) in participants with moderately to severely active Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract).
Protocol Amendment History 3 changes
notable Trial sites expanded: 363 -> 367 locations 2026-07-07
notable Trial sites expanded: 358 -> 363 locations 2026-06-06
notable Trial sites expanded: 324 -> 358 locations 2026-05-09
Trial Details
NCT Number NCT07196722
Lead Sponsor Janssen Research & Development, LLC
Conditions Crohn Disease
Enrollment 1,092 participants
Start Date 2025-10-03
Primary Completion 2028-09-19 (estimated)
Study Completion 2032-10-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-31